TOLREMO therapeutics’ Post

It's time to talk about mushrooms! Or rather how our client Heidelberg Pharma AG wants to use alpha-Amanitin, the deadly poison found in death cap mushrooms to fight cancer. Find out more about Heidelberg's antibody-drug conjugate (ADC) technology in Beyond Biotech - the podcast from Labiotech.

Did you know that the toxins in some mushrooms could treat cancer? 🍄 ☠️ Death cap mushrooms are a poisonous species that contain alpha-Amanitin. Heidelberg Pharma AG has used this toxin to create a drug for cancer. The drug recently received orphan drug designation from the U.S. FDA, and is being tested in clinical trials. 🏥 Labiotech has been in conversation with Heidelberg’s CEO, Andreas Pahl, about how this deadly toxin has been made into a drug that could potentially treat a range of cancers. 💊 Tune into the latest episode of the Beyond Biotech Podcast to know more! 👇 https://lnkd.in/dS6ZbxAm #BeyondBiotechPodcast #cancerresearch #clinicaltrials #biotech #healthcareinnovation #oncology #cancertherapies #medicalresearch #biotechnews

Cancer therapies have come a long way — but what if we told you scientists are now figuring out how to kill cancer cells through your body's own natural immunological response? That's the case with Recolony AG, a biotech startup developing a bacteria-based oral therapy that kicks your immunological gears into motion. They're a University of Zurich spin-off, and their co-founder Ana Montalban-Arques is one of the brains behind the operation. In this episode you will learn: 🦠 Exactly how bacteria can kill cancer 🧫 How to reach proof of concept in biotech 🛣️ What are the possible avenues after a tradesale 🤰 How to combine entrepreneurship and motherhood Click the link in the comments to listen to the full episode! - #swisspreneur #startup #entrepreneur #podcast #recolony #cancer #biotech #medtech #bacteria #coloncancer #colorectalcancer #microbiome #gutmicrobiome #immune #uzh

Clora CEO Rahul Chaturvedi hosts an inspiring new episode of the Biotech2050 podcast featuring Robert Ang, CEO of Vor Bio. Dive into an engaging discussion on next-gen cancer therapies, including Vor’s shielded CD33-deleted stem cell transplants and CAR-T cell therapies for AML and MDS. Robert also shares his unique approach to building passionate and impactful teams. Listen using the link below. #Clora #biotech #podcast #cancer #stemcelltransplant

🚀 Exciting News from NLC Health Ventures! Introducing our venture, Aerion Bioscience, set to revolutionize early lung cancer detection and transform global outcomes. 🌐Lung cancer, the second most common cancer worldwide, has long posed significant challenges in early detection, contributing to its devastating impact on global health. With more than 2.2 million new cases reported in 2020 and 1.8 million deaths, the need for a reliable, non-invasive screening solution is more pressing than ever. 🔬 Aerion Bioscience's Mission: Aerion Bioscience is on a mission to change the narrative surrounding lung cancer. Our innovative approach focuses on developing a simple, non-invasive blood test that will significantly improve early detection and survival outcomes for millions of high-risk individuals. With a validated 6-protein biomarker panel, we aim to fill the void left by existing screening methods and empower doctors to proactively monitor patients during routine visits. 👋 Welcome to the Team: Let's extend a warm welcome to the visionary leader driving Aerion Bioscience forward— Dr. Axel Schumacher, our CEO. Together, we are dedicated to reshaping the future of lung cancer detection and saving lives.

🔬 Ever wondered how working at an Innovation Space may enhance your ability to collaborate and fast-forward your next groundbreaking innovation?   Basel-based Engimmune Therapeutics and the Swiss innovation center CSEM, housed at the Switzerland Innovation Park Basel Area - Main Campus HQ, discuss in an interview how and why they started to work together to advance cancer treatment. Watch it below 👇 Engimmune Therapeutics, also part of BaseLaunch's portfolio, is a spin-off from ETH Zürich on a quest to revolutionize cancer treatment with soluble T cell receptors (TCR). CSEM, a landmark of Swiss technological innovation, is on a mission to bridge the gap between research and industry. The synergy between Engimmune’s TCR technology and CSEM’s microfluidic prowess has set the stage for a leap in cancer therapy development. By encapsulating individual TCR tests in microscopic droplets, cross-contamination is eliminated, ensuring precise and reliable results. This innovation dramatically accelerates the screening process, turning what used to take months into a matter of weeks, and significantly increasing the number of TCR candidates that can be de-risked in preparation for clinical trials. Read the full article right here: https://lnkd.in/eiGCKE3Y Rodrigo Vazquez-Lombardi | Felix K. #innovation #startups #collaboration #healthcare #lifescience

🌟 Another exciting event on 2 Bridge’s agenda! 🌟 Tomorrow, Eric Ciamporcero from our team is heading to the "R𝐞𝐜𝐞𝐧𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐭𝐨 𝐈𝐦𝐦𝐮𝐧𝐨-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 (2𝐧𝐝 𝐞𝐝𝐢𝐭𝐢𝐨𝐧)" event, and we couldn't be more excited! Why is this event a must-attend? The program gathers world-renowned experts who will present their latest work in sessions focused on: - Car T Cells - Precision immuno-oncology - Immune-escape - Glycobiology in cancer - Cross-talk myeloid cells - Tumor-host interactions - Translational research At 2 Bridge, we're always on the lookout for innovative ways to push the boundaries in biotech. Eric's attendance at this event means we’re at the heart of the latest advancements, ready to transform cutting-edge research into real-world value. The revolution in cancer immunotherapy is here, and 2 Bridge is right in the mix—learning, contributing, and driving innovation to provide the best solutions to our clients. 💡🔥 #Biotech #ImmunoOncology #CancerResearch #TranslationalResearch #HealthcareInnovation #CancerImmunotherapy #ScientificAdvancements

Outpace Bio Secures $144M in Series B Funding for AI-Enhanced Cancer Therapy - Funding and Investors: Outpace Bio raised $144M in Series B financing, with contributions from RA Capital Management, Qatar Investment Authority, and other investors, bringing total funding to around $200M. - Focus and Leadership: Led by Marc Lajoie, Outpace Bio develops engineered T cell therapies using AI for treating solid tumors. - Product Development: The financing will support advancing T cell product candidates, including OPB-101, targeting ovarian and other cancers, with clinical trials expected in 2025. Subscribe to our daily newsletter here for more AI news https://lnkd.in/dV8hV7cC #AI #Healthcare #VentureCapital #Innovation #Technology #bigdata #ArtificialIntelligence #Futurism #Entrepreneurship #fundraising

#WhatsUpWednesday this week features The Alliance for Artificial Intelligence in Healthcare (AAIH) Vice Chair Maria Luisa Pineda, PhD. and her company Envisagenics, for which she is the CEO and Co-founder. Learn more about what Envisagenics is doing to raise money for cancer drug targets created by alternative RNA splicing in the article below!

Freenome, like other liquid biopsy developers such as Grail, has repeatedly raised large financing rounds to fund studies to validate its technology. Freenome’s funding passed the $1 billion mark in January 2022, when Roche invested $290 million weeks after the liquid biopsy company raised $300 million in a series D round. The money has enabled Freenome to advance technology for detecting cell-free biomarkers that show a patient may have cancer. Since starting out in 2014, the company has worked to analyze DNA, RNA, proteins and more using machine learning to detect signs of tumors. #fundraising #capitalraising #capitalmarkets #financing #technology #biotech #freenome